Light induced killing of Cancer-Cells

http://content.karger.com/ProdukteDB/produkte.asp?Doi=282785


Laser-Induced Fluorescence Diagnosis and Photodynamic Therapy of Human Renal Cell Carcinoma
S. Pomera, G. Grashevb, H. Sinnb, T. Kälblea, G. Staehlera

aUrological Department, University of Heidelberg,
bInstitute of Nuclear Medicine, German Cancer Research Center, Heidelberg, Germany

Address of Corresponding Author

Urol Int 1995;55:197-201 (DOI: 10.1159/000282785)

goto top of page Key Words

* Laser-induced fluorescence diagnosis
* Photodynamic therapy
* Renal cell carcinoma
* Nephron sparing

goto top of page Abstract

Photodynamic therapy (PDT) has recently attracted mucht attention, especially among urologists, because it appears to be a selective form of cancer treatment which causes minimal damage to normal surrounding tissues. In this study we made use of a new class of photosensitizers for the laser-induced fluorescence diagnosis (LIFD) and photodynamic therapy of human renal cell carcinoma xenotransplanted into nude mice. The purpose of this study was to evaluate the recently developed photosensitizing drug THOPP-MPEG for its efficacy as photosensitizer for LIFD and PDT of renal cell carcinoma. THOPP-MPEG was injected intraperitoneally (0.5 µg/g body weight) into the mice 6–8 days after tumor transplantation. On the 18th day after transplantation, the tumors reached a diameter of 3–4 mm. Seven days after administration of the drug the tumor-bearing kidney was irradiated percutaneously with a total light dose of 2 × 60 J/cm2 and a power density in the irradiated area of less than 150 mW/cm2. A continuous-beam argon-pumped dye laser (656 nm) was used. After excitation with laser light (488–514 nm), the vital tumor clusters and the surrounding tissues invaded with tumor cells showed intense red coloration by laser-induced fluorescence. Subsequent to the light exposure (656 nm), a heavy tumor necrosis of up to 3–5 mm resulted. No THOPP-MPEG phototoxicity in normal surrounding tissue at a dose of up to 100 mg/ kg body weight was seen. We believe the future role of PDT in the management of tumors of the kidney to be adjuvant within the concept of conservative kidney-preserving surgery.

Copyright © 1995 S. Karger AG, Basel

Author Contacts

Prof. S. Pomer, Urological Department, University of Heidelberg, Im Neuenheimer Feld 110, D-69120 Heidelberg (Germany)

goto top of page Article Information

Received: May 11, 1994
Accepted after revision: June 15, 1995
Published online: February 03, 2010
Number of Print Pages : 5



CITED BY


Photodynamic therapy for urological malignancies: past to current approaches.
Jehonathan H Pinthus, Arjen Bogaards, Robert Weersink, Brian C Wilson, John Trachtenberg
Prostate Cancer Center, University Health Network and Department of Medical Biophysics, Ontario Cancer Institute, University of Toronto, Toronto, Ontario, Canada.
PURPOSE: Modern PDT for urological tumors is a potentially selective approach in which in situ photosensitization by a nontoxic drug, locally activated by light, generates cytotoxic reactive oxygen species, causing cell death. While urological clinical experience with PDT is largely limited to treatment for superficial bladder cancer, the advent of novel photosensitizers and technologies for treatment planning, light delivery and dosimetry, PDT for prostate and other urological cancers appears increasingly realistic. MATERIALS AND METHODS: We reviewed the current literature on PDT for urological tumors, in addition to recent emerging data from our laboratory and elsewhere. RESULTS: Remarkable progress has been made in the field of photochemistry and photobiology. Together with improved optical delivery and imaging systems PDT holds promise as an alternative, minimally invasive and potentially curative treatment for localized solid tumors as well as for palliative treatment for isolated, clinically problematic metastases. CONCLUSIONS: Current experience with photodynamic therapy using contemporary photosensitizing agents and light sources is mainly restricted to in vivo experimental models and early phase clinical trails. However, ongoing preclinical work and clinical trials indicate that safer and effective PDT treatments in uro-oncology are imminent.
Keywords: pdt; urological; photodynamic; photodynamic therapy; urological malignancy; urological tumor; cau; current approache; tumor; current; malignancy; therapy; trail; cancer; light;


Oncologic photodynamic therapy photosensitizers: a clinical review.
Ron R Allison, Claudio H Sibata
21st Century Oncology, Greenville, NC 27834-3764, USA.
A myriad of naturally occurring and synthetic structures are capable of transferring the energy of light. Few, however, allow for this energy transfer to enable a type II photochemical reaction which, as currently practiced, is a fundamental component of photodynamic therapy. Even fewer of these agents, aptly termed photosensitizers, have found success in the treatment of patients. This review will focus on the oncologic photosensitizers that have come to clinical trial with outcomes published in peer reviewed journals. Based on a clinical orientation the qualities of successful photosensitizers will be examined, how current drugs fare and potential future options explored.
Keywords: photosensitizer; photodynamic; photodynamic therapy; oncologic; clinical review; therapy; review; clinical; energy; transfer; peer review; review journal; future option; peer; photochemical reaction;


MUST READ

MUST READ 2